Lichen Planus – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Lichen planus is a chronic autoimmune disease impacting the skin, oral and genital mucosa, scalp, and nails. Its lesions are characterized by six features known as the six P's: flat-topped, purple, polygonal, pruritic, papules, and plaques. These papules and plaques, which are itchy and violet in color, are typically found on the wrists, lower back, and ankles. Wickham striae, a lattice-like network of white lines, can be observed, especially on the buccal mucosa, which may also exhibit erosions. Drug-induced lichen planus, or lichenoid drug eruption, often presents similarly and is mainly distributed due to photosensitivity, making it hard to distinguish from the idiopathic form. The exact cause of lichen planus is unknown. However, it is believed to be a T-cell-mediated autoimmune disease triggered by various external factors such as viruses, drugs, or allergens. These factors lead to changes in self-antigens on the skin and activation of cytotoxic CD8+ T cells, causing T-cell targeting and apoptosis of basal keratinocytes. Several conditions, including lupus erythematosus (LE), lichen nitidus, psoriasis, secondary syphilis, pityriasis rosea, erythema dyschromicum perstans, graft versus host disease, and keratosis lichenoides chronica, may mimic lichen planus. Differentiating between LP and LE can be challenging, especially when they affect the scalp or mouth. A biopsy with direct immunofluorescence (DIF) is valuable in such cases. Co-occurrence of both diseases has been reported and may be linked to antimalarial treatments for LE. Cutaneous lichen planus often resolves on its own within one to two years, but hyperpigmentation can persist. Oral lichen planus may clear spontaneously within five years but frequently has a chronic, recurring nature. Hair loss from lichen planopilaris is permanent. Withdrawal of the causative medication is the primary treatment for drug-induced lichen planus. Topical corticosteroids are the initial treatment for mucosal erosive lichen planus, while systemic corticosteroids are an option for severe, widespread cases affecting the mouth, skin, or genitals. Dermatologist referral for systemic therapy with expensive and potentially toxic oral retinoids or immunosuppressants may be necessary for severe, treatment-resistant lichen planus. Oral involvement occurs in approximately 50% of cases and may occur independently of skin lesions. Vulvar and vaginal mucosae are frequently affected, and undiagnosed vulvar lichen planus is common in women with oral mucosal symptoms. Genital involvement, particularly of the glans penis, is frequent in men, and nail involvement is seen in up to 10% of cases. The average age at diagnosis is 62.4 years.
Thelansis’s “Lichen Planus Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lichen Planus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Lichen Planus across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Lichen Planus Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment